BIOMAT Database Logo BIOMAT Database Logo

Biomarker Discovery and Validation: Statistical Considerations. 2021

Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. Electronic address: ou.fang-shu@mayo.edu.

Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D057285 Precision Medicine Clinical, therapeutic and diagnostic approaches to optimal disease management based on individual variations in a patient's genetic profile. Individualized Medicine,Predictive Medicine,P Health,P-Health,Personalized Medicine,Theranostics,Medicine, Individualized,Medicine, Personalized,Medicine, Precision,Medicine, Predictive,Theranostic
D035843 Biomedical Research Research that involves the application of the natural sciences, especially biology and physiology, to medicine. Medical Research,Experimental Medicine,Investigational Medicine,Investigative Medicine,Research, Biomedical,Research, Medical,Medicine, Experimental,Medicine, Investigational,Medicine, Investigative

Related Publications

Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Biomarker discovery and validation.
September 2006, Clinical chemistry,
Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery.
April 2012, Journal of proteome research,
Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Cancer biomarker discovery and validation.
June 2015, Translational cancer research,
Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation.
August 2021, Nature protocols,
Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Neuroimaging-based biomarker discovery and validation.
August 2015, Pain,
Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective.
September 2004, Pharmacogenomics,
Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Statistical Aspects in Proteomic Biomarker Discovery.
January 2016, Methods in molecular biology (Clifton, N.J.),
Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Proteomic Workflows for Biomarker Identification Using Mass Spectrometry - Technical and Statistical Considerations during Initial Discovery.
August 2013, Proteomes,
Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Statistical considerations when analyzing biomarker data.
November 2015, Clinical immunology (Orlando, Fla.),
Fang-Shu Ou, and Stefan Michiels, and Yu Shyr, and Alex A Adjei, and Ann L Oberg
Biomarker discovery and validation: technologies and integrative approaches.
August 2004, Trends in biotechnology,
Copied contents to your clipboard!